Preclinical Studies of OBI-999: A Novel Globo H-Targeting ... - PubMed
21-205. Phase I/II (phases 1 and 2 combined) Investigator. Anna M. Varghese. Co-Investigators. Eileen M. O'Reilly. Diseases. Solid Tumors. Locations. Memorial Sloan Kettering Cancer Center. ClinicalTrials.gov ID. NCT04084366. ClinicalTrials.gov. Visit ClinicalTrials.gov for full clinical trial description.
First-in-human study of OBI-999: A globo H-targeting antibody-drug ...
OBI-999 exhibited non-linear pharmacokinetics from 0.4 mg/kg to 1.6 mg/kg, with lower clearance at higher doses. A retrospective validated automated immunohistochemistry assessment indicated 50% of patients with advanced solid tumors had high Globo H staining (H-score cutoff ≥100).
Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug ...
DR. OKWUCHUKWU GINIKA OBI MD. NPI 1285044495. Anesthesiology - Pain Medicine in Las Vegas, NV. Quality Rating: 78.99 out of 100 score. NPI Status: Active since April 28, 2014. Contact Information. 1900 N NELLIS BLVD. LAS VEGAS, NV. ZIP 89115. Phone: (702) 880-4193. Get Directions Reviews. NPI Profile. NPI Record. Similar Providers Nearby.
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug ...
Dr. Okwuchukwu Obi, MD is a Pain Medicine Specialist in Las Vegas, NV and has 10 years experience. They graduated from Medical University of South Carolina. They currently practice at Practice. Dr. Obi has experience treating conditions like Chronic Pain, Spondylitis and Postherpetic Neuralgia among other conditions at varying frequencies.
Abstract 5946: OBI-999, an anti-Globo H antibody drug conjugate ...
OBI-999 is an antibody drug conjugate (ADC) consisting of a GH-specific monoclonal antibody conjugated with monomethyl auristatin E (MMAE) through a cathepsin B cleavable linker. MMAE is known to induce immunogenic cell death (ICD) which involves in the activation of cytotoxic T lymphocyte-driven adaptive immunity with long-term immunological ...
TARGETED DRUG THERAPY First-in-Human Study of OBI-999, a Globo H ...
OBI-999 is a novel first-in-class Antibody Drug Conjugate (ADC) with a proprietary linker technology that provides a consistent Drug-to-Antibody ratio (DAR) for cancer treatment targeting Globo H. OBI-999 uses a Globo H antibody to target cancer cells of high Globo H expression.
Pre-clinical Studies of OBI-999: a Novel Globo H ... - ResearchGate
Vanderbilt University Medical Center. Fellowship. Find information about and book an appointment with Dr. Okwuchukwu G Obi, MD in Las Vegas, NV. Specialties: Anesthesiology.
OBI Pharma Announces First Cancer Patient Enrolled on OBI-999 in Phase ...
OBI-999 belongs to a class of Antibody Drug Conjugates (ADCs) anti-cancer agents and there are 5 ADCs that were approved by FDA in 2019 and 2020. Treatment with ADC provides better safety margin and efficacy than chemotherapy due to antigen specificity.
First-in-human study of OBI-999: A globo H-targeting antibody-drug ...
Purpose: OBI-999 is a novel antibody-drug conjugate comprising the Globo H-targeting antibody (OBI-888) linked to the cytotoxic payload monomethyl auristatin E. OBI-999 demonstrated excellent dose-dependent tumor growth inhibition in breast, gastric, and pancreatic cancer xenograft models as well as a lung cancer patient-derived xenograft model.
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and ...
OBI-999, a novel antibody-drug conjugate, is derived from a conjugation of a GH-specific mAb with a monomethyl auristatin E (MMAE) payload through a site-specific ThioBridge and a cleavable linker. OBI-999 high homogeneity with a drug-to-antibody ratio of 4 (>95%) was achieved using ThioBridge.